The continued rise in global rates of obesity, which is typically accompanied by elevations in systemic insulin and IGF-I levels, suggests that efforts to develop pharmaceutical agents that reduce this signaling for cancer prevention and treatment are particularly warranted. The gene discussed is IGF1; the disease is obesity due to melanocortin 4 receptor deficiency.